Tomorrow’s Medicine
Thomas Morrow, MD
It is safe to say that few people read a June 5, 1981, report in the CDC’s Morbidity and Mortality Weekly Report that described five cases of a rare lung infection, Pneumocystis carinii pneumonia (PCP), in previously healthy young gay men. The first story about HIV/AIDS published in the New York Times…
News & Commentary
Clinical benefits associated with new cancer therapies do not justify the high prices for the medications, and some value-based payment system is needed, according to a study published in the Journal of Oncology Practice. That’s especially true regarding incremental costs, the difference in total drug price between the novel medications and standard treatment.
Peter Wehrwein
Atul Gawande is a splashy choice to head up the Amazon–Berkshire Hathaway–JP Morgan Chase health care initiative. Stat called the 52-year-old surgeon, Harvard professor, and prolific New Yorker staff writer an “all-around health care celebrity.” Gawande is royalty in Boston’s high-powered…
News Wire
The head of a small biotechnology company points out that businesses need to make money.
Smaller niche health plans see promise where the big guys see risk.
Rules issued by the Trump administration would make it easier for small employers to shift into the large employer market
Therapy approved for adults and children with refractory PMBCL or who have relapsed after two or more prior lines of therapy
Sarah Kwon
Adam Cifu, MD
New guidelines from the American College of Physicians recommend less stringent blood sugar targets for most people with diabetes. Other professional groups think that’s a terrible idea.
Legislation & Regulation
Richard Mark Kirkner
Anna Sinaiko
Price transparency mandates are catching on. But they may codify that which hasn’t worked all that well so far.
Viewpoint
Craig Kasten
Health care is increasingly becoming like other retail encounters—a transaction between buyers and sellers. Patients, providers, payers—everybody needs to adjust. With the right technology and the will to change, the process of paying for health care can become as simple—and as painless—as getting a haircut.
Now available

Precision medicine, big data, Alzheimer’s Disease, migraine, and RNA therapeutics.
Learnings from the April 2018 meeting.
Edited by Jill Condello, PhD, ICON Access, Commercialisation & Communications

CURRENT ISSUE June 2018

Medicine Doesn’t Work If Patients Don’t Take It

And yet, nonadherence not only persists, but the costs of more effective medications makes the problem worse. As our cover story notes, nonadherence impairs and even shortens life, and that’s toxic for a health system that has trouble controlling costs as it is.

Mainly, though, this issue is about managing diabetes. Our story looks at how Nevadan lawmakers are pushing a bill that requires more transparency from drugmakers. As other states mull similar action, pharma companies push back.

We  also look at new guidelines from the American College of Physicians that recommend less-aggressive blood sugar targets. Other professional groups think that’s a terrible idea.

Meanwhile, researchers have proposed a new taxonomy that divides diabetes into clusters instead of types.

UPCOMING MEETINGS
Philadelphia, PA
July 16-17, 2018
Los Angeles, CA
July 16-17, 2018
Alexandria, VA
July 16-17, 2018
Alexandria, VA
July 16-17, 2018
San Diego, CA
July 23-24, 2018
Philadelphia, PA
July 23, 2018
News & Commentary
Antibiotic resistance increases the cost of treating a bacterial infection by $1,383 and adds $2.2 billion to the country’s health care spending. Inpatient care is the biggest contributor to the incremental cost. Also costs related to antibiotic resistance were higher for older people and those in poor health.
Priced out of health care
Timothy Kelley
Even the most effective drug is useless if people don’t take it because it’s so expensive. Today’s high prices are pushing more and more patients into nonadherence. It’s a prescription for trouble for us all.
Too many Americans are skipping prescribed medications because they find them too expensive. That foretells trouble for payers—and for patients. On this page, you’ll find several relevant facts and numbers.